Dr Reddys unveils Methylphenidate Hydrochloride ER Tablets in US
Concerta is indicated to treat attention deficit hyperactivity disorder(ADHD).
Hyderabad: Dr. Reddys Laboratories Ltd. on Thursday announced the launch of Methylphenidate Hydrochloride Extended-Release Tablets USP, a therapeutic equivalent generic version of Concerta, in various strengths, in the USA market.
The drug was approved by the U.S. Food and Drug Administration (USFDA), a press release from the drug maker said.
Concerta is indicated to treat attention deficit hyperactivity disorder (ADHD).
Read also: Dr Reddys launches generic version of Cuprimine Capsules in US
Dr. Reddys Methylphenidate Hydrochloride Extended- Release Tablets, USP are available in strengths of 18 mg, 27 mg, 36 mg, and 54 mg tablets in bottle count sizes of 100, it said.
Read also: Dr Reddys enters hospital nutrition segment with launch of Celevida Maxx in India
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.